Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, ismodifiable, and associates with future cardiovascular deaths

Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths Maija Ruuth 1,2 , Su Duy Nguyen 1 , Terhi Vihervaara 3 , Mika Hilvo 3 , Teemu D. Laajala 4,5 , Pradeep Kumar Kondadi 6 , Anton Gistera˚ 7 , Hanna La¨hteenma¨ki 1 , Tiia Kittila¨ 1 , Jenni Huusko 8 , Matti Uusitupa 9 , Ursula Schwab 9,10 , Markku J. Savolainen 11,12 , Juha Sinisalo 13 , Marja-Liisa Lokki 14 , Markku S. Nieminen 13 , Antti Jula 15 , Markus Perola 15,16 , Seppo Yla¨-Herttula 8,17 , Lawrence Rudel 18 , Anssi O ¨o¨rni 19 , Marc Baumann 20 , Amos Baruch 21 , Reijo Laaksonen 3,22,23 , Daniel F.J. Ketelhuth 7 , Tero Aittokallio 4,5 , Matti Jauhiainen 15,24 , Reijo Ka¨kela¨ 25,26 , Jan Bore´n 6 , Kevin Jon Williams 6 , Petri T. Kovanen 1 , and Katariina O ¨o¨rni 1,25 * 1 Atherosclerosis Research Laboratory, Wihuri Research Institute, Haartmaninkatu 8, 00290 Helsinki, Finland; 2 Research Programs Unit, Faculty of Medicine, University of Helsinki, Haartmaninkatu 8, P.O. Box 63, 00014 University of Helsinki, Finland; 3 Zora Biosciences, Biologinkuja 1, 02150 Espoo, Finland; 4 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Tukholmankatu 8, P.O. Box 20, 00014 University of Helsinki, Finland; 5 Department of Mathematics and Statistics, University of Turku, Vesilinnantie 5, 20014 University of Turku, Finland; 6 Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, SU Sahlgrenska, 41345 Gothenburg, Sweden; 7 Department of Medicine, Karolinska University Hospital, Karolinska Institute, Solna 171 76 Stockholm, Sweden; 8 Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Yliopistonranta 1, P.O. Box 1627, 70211 Kuopio, Finland; 9 Institute of Public Health and Clinical Nutrition, School of Medicine, University of Eastern Finland, Yliopistonranta 1, P.O. Box 1627, 70211 Kuopio, Finland; 10 Institute of Clinical Medicine, Internal Medicine, Kuopio University Hospital, Puijonlaaksontie 2, P.O. Box 100, 70029 Kuopio, Finland; 11 Research Unit of Internal Medicine, University of Oulu, Pentti Kaiteran katu 1, P.O. Box 8000, 90014, Oulu, Finland; 12 Medical Research Center, Oulu University Hospital, Pentti Kaiteran katu 1, P.O. Box 8000, 90014 Oulu, Finland; 13 Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 340, 00029 Helsinki, Finland; 14 Transplantation Laboratory, Medicum, University of Helsinki, Haartmaninkatu 3, P.O. Box 21, 00014 Helsinki, Finland; 15 Genomics and Biomarkers Unit, Department of Health, National Institute for Health and Welfare, Genomics and Biomarkers Unit, Mannerheimintie 166, P.O. Box 30, 00271 Helsinki, Finland; 16 Institute for Molecular Medicine Finland and Diabetes and Obesity Research Program, University of Helsinki, Haartmaninkatu 8, P.O. Box 63, 00014 University of Helsinki, Finland; 17 Heart Center and Gene Therapy Unit, Kuopio University Hospital, Puijonlaaksontie 2, P.O. Box 100, 70029 Kuopio, Finland; 18 Department of Biochemistry Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA; 19 Information Systems, A ˚bo Akademi University, Fa¨nriksgatan 3A, 20500 Turku, Finland; 20 Meilahti Clinical Proteomics Core Facility, Faculty of Medicine, University of Helsinki, Haartmaninkatu 8, P.O. Box 63, 00014 University of Helsinki, Finland; 21 Genentech Research and Early Development, 1 DNA Way Mailstop 258A, South San Francisco, CA 94080, USA; 22 Finnish Cardiovascular Research Center, University of Tampere, Kalevantie 4, 33100 Tampere, Finland; 23 Finnish Clinical Biobank Tampere, University Hospital of Tampere, Arvo Ylpo¨n katu 6, 33520 Tampere, Finland; 24 Minerva Foundation Institute for Medical Research, Tukholmankatu 8, 00290 Helsinki, Finland; 25 Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Viikinkaari 1, P.O. Box 65, 00014 University of Helsinki, Finland; and 26 Helsinki University Lipidomics Unit, Helsinki Institute for Life Science (HiLIFE), Viikinkaari 1, P.O. Box 65, 00014 University of Helsinki, Finland Received 7 December 2017; revised 8 March 2018; editorial decision 18 May 2018; accepted 21 May 2018; online publish-ahead-of-print 4 July 2018 See page 2574 for the editorial comment on this article (doi: 10.1093/eurheartj/ehy387) Aims Low-density lipoprotein (LDL) particles cause atherosclerotic cardiovascular disease (ASCVD) through their retention, modification, and accumulation within the arterial intima. High plasma concentrations of LDL drive this disease, but LDL quality may also contribute. Here, we focused on the intrinsic propensity of LDL to aggregate upon modification. We examined whether inter-individual differences in this quality are linked with LDL lipid composition and coronary artery disease (CAD) death, and basic mechanisms for plaque growth and destabilization. ............................ ............. ............. .................. ............. ............. ............................... ............. ............. .................. ............. ......... * Corresponding author. Tel: þ358 96814133, Fax: þ358 9637476, Email: kati.oor[email protected] V CThe Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] European Heart Journal (2018) 39, 2562–2573 BASIC SCIENCE doi:10.1093/eurheartj/ehy319 Coronary artery disease Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/27/2562/5049093 by Tampere University Library user on 22 August 2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Methods and results We developed a novel, reproducible method to assess the susceptibility of LDL particles to aggregate during lipolysis induced ex vivo by human recombinant secretory sphingomyelinase. Among patients with an established CAD, we found that the presence of aggregation-prone LDL was predictive of future cardiovascular deaths, independently of conventional risk factors. Aggregation-prone LDL contained more sphingolipids and less phosphatidylcholines than did aggregation-resistant LDL. Three interventions in animal models to rationally alter LDL composition lowered its susceptibility to aggregate and slowed atherosclerosis. Similar compositional changes induced in humans by PCSK9 inhibition or healthy diet also lowered LDL aggregation susceptibility. Aggregated LDL in vitro activated macrophages and T cells, two key cell types involved in plaque progression and rupture. ............................ ............. ............. .................. ............. ............. ............................... ............. ............. .................. ............. ......... Conclusion Our results identify the susceptibility of LDL to aggregate as a novel measurable and modifiable factor in the progression of human ASCVD. 䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏䊏 Keywords Low-density lipoprotein •Atherosclerosis •Cardiovascular death •Sphingomyelin •Lipidomics Introduction An elevated plasma concentration of low-density lipoprotein cholesterol (LDL-C) is a primary causal factor in the development of atherosclerotic cardiovascular disease (ASCVD) 1 and significantly contributes to the total cardiovascular risk. 2 However, even after efficient LDL-C-lowering, a substantial residual risk for ASCVD events remains. 3–5 Atherosclerosis arises from subendothelial retention, or trapping, of LDL within the arterial intima, and several steps are required for plasma LDL-C to provoke normal arteries to become diseased. The retained lipoproteins become modified by arterial-wall enzymes and oxidants, 6,7 tend to aggregate, 8 and aggregated lipoprotein-derived particles are found both in human and in experimentally induced atherosclerotic lesions in animal models. 9–12 The intimal processes triggering aggregation of LDL particles have been proposed to include lipid peroxidation and proteolytic and lipolytic digestion of LDL by local enzymes, such as the mast cell chymase having chymotrypsin-like activity, 13 the group V secretory phospholipase A 2 (PLA 2 ), 14 which is produced by macrophages, as well as the secretory sphingomyelinase (SMase), which is released by macrophages and endothelial cells. 15 Aggregation enhances the binding of lipoproteins to the arterial extracellular matrix, 8 and their large size makes egress back across the endothelium nearly impossible. 7 Moreover, aggregated LDL induces the formation of foam cells, a hallmark of lesions at all stages of atherogenesis. 14,16,17 Indeed, the development of an atherosclerotic lesion involves a series of maladaptive responses of innate and adaptive immune cells to the retained, modified, and aggregated lipoprotein-derived material. 18,19 In this study, we focused on the intrinsic susceptibility of circulating LDL particles to aggregate upon modification, and, for the first time, examined inter-individual differences in this quality. This study aimed to determine whether the degree of aggregation susceptibility of LDL can predict future cardiovascular deaths and whether it can be modified by nutritional or medical treatment. Materials and methods Human plasma Human blood plasma samples were obtained from healthy volunteers (Finnish Red Cross Blood Service, Helsinki, Finland), 100 samples derived from subjects participating in the Health 2000 Health Examination Survey, 20 48 samples from Corogene survey, 21 57 samples from SYSDIET (Systems biology in controlled dietary interventions and cohort studies) survey, 29 samples from the 18-week diet group and 28 samples from the 24-week diet group, 22,23 and 40 samples from the EQUATOR study. 24 The use of human material conformed to the principles outlined in the Declaration of Helsinki, and the studies were approved by the local ethics committees. Written informed consent was obtained from all participants. Isolation of LDL and lipid and lipoprotein measurements Lipid measurements Fasting plasma total cholesterol and triglycerides were enzymatically measured (Roche Diagnostics, GmbH, Mannheim, Germany). ApoB-100 content was measured with ELISA-kit (MABTECH, Nacka, Sweden). LDL isolation LDL (d= 1.019 to 1.063 g/mL) was isolated from plasma by KBr-based sequential ultracentrifugation. 25 LDL concentrations are expressed as their protein concentrations, which were determined by the BCA protein assay (Pierce, Rockford, USA) using bovine serum albumin as a standard, or as apoB-100 concentration determined by ELISA. Translational perspective Accumulation of low-density lipoprotein (LDL)-derived cholesterol in the arterial wall causes atherosclerotic cardiovascular disease (ASCVD). High plasma concentrations of LDL drive this disease, but LDL quality may also contribute. Here, inter-individual differences in LDL lipidome were found to determine the susceptibility of LDL to aggregate during lipolysis by human recombinant secretory sphingomyelinase. The presence of aggregation-prone LDL in plasma predicted future cardiovascular death in coronary artery disease patients. Interventions in pre-clinical models to rationally alter LDL composition lowered its susceptibility to aggregate and slowed atherosclerosis development. Our results identify the susceptibility of LDL to aggregate as a novel measurable and modifiable factor in the progression of human ASCVD. Aggregation-prone LDL predicts CAD death 2563 Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/27/2562/5049093 by Tampere University Library user on 22 August 2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Measurement of LDL aggregation Development of a method to quantify person-to-person variability in LDL aggregation-susceptibility is available in Supplementary material online,Methods and Figures S1–S3. In the assay we developed, LDL isolated from human plasma was extensively dialysed against 20 mM MES buffer, pH 5.5, containing 150 mM NaCl, 2 mM MgCl 2 , 2 mM CaCl 2 , and 50mM ZnCl 2 . The sample was diluted with the same buffer to give a final concentration of 0.2 mg of apoB-100/mL, then human recombinant secretory sphingomyelinase (hrSMase) was added to to give a final enzyme concentration of 75 mg/mL, and the mixture was incubated at þ37C. The size of LDL was determined immediately and the hourly up to 6 h. An aliquot was taken at the same time points for phosphorylcholine measurement. The degree of sphingomyelins (SM) hydrolysis was determined by measuring the phosphorylcholine content from the samples with Amplex Red reagent (Invitrogen). SMPC-, and LPC-enrichment of LDL ex vivo LDL was enriched ex vivo with SM, PC, or LPC using phospholipid vesicles, as described in detail in Supplementary material online, Methods. Mice Large ‘empty’ vesicle-treated mice Human APOB 100 transgenic, Ldlr -/- -mice on a chow diet, with food and water received ad libitum (13–19 weeks old for control with phosphatebuffered saline (PBS) and 19 weeks old for large ‘empty’ vesicle (LEV), weight 30–33g) (n= 16 per group) were injected once with PBS or with LEVs (also known as large unilamellar vesicles, 100-nm in diameter, dosed at 1000 mg PC/kg body weight). One hour after PBS or LEVs injection, plasma was collected, and the d< 1.063g/mL KBr fraction was isolated using ultracentrifugation. Because LEVs can appear in the LDL density range, we collected the supernatant fraction after ultracentrifugation, loaded it onto a Superose 6 HR column (size-exclusion FPLC), and eluted with 150 mM NaCl, 1 mM EDTA, pH 7.4. LDL fractions, which came out after the peak for LEVs and VLDL, were pooled and re-loaded onto the Superose 6 HR column, eluted with 150 mM NaCl, 1 mM EDTA pH 7.4, at which point no peak for LEVs or VLDL was detectable. LDL fractions were pooled in pairs (sample size, n= 16) and protein concentration was measured. The animal procedures were approved by the Animal Ethical Committee at the Gothenburg University. Myriocin-treated mice Male Ldlr -/- ,Apob 100/100 mice on the C57BL/6J genetic background were obtained from Jackson Laboratory (Bar Harbor, ME, USA) and housed in the National Laboratory Animal Center of the University of Eastern Finland. Mice were divided into control (n= 11) and myriocin (n=11) groups. The mice were fed on an high-fat atherogenic diet (21% milk fat, 0.2% cholesterol; Harlan Teklad; TD88137; colloquially called the ‘Western’ diet) from 14 to 22 weeks of age onwards, with food and water received ad libitum. Myriocin (0.3 mg/kg) (Biomol Research Laboratories Inc.) or PBS as control was injected intraperitoneally (i.p.) three times per week for 10 weeks. After 10weeks on high-fat diet with myriocin/PBS treatment, mice were fasted for 4 h and terminal anaesthetised with isoflurane inhalation (Vetflurane 1000mg/g, Virbab animal health). Blood was collected by heart puncture. These animal procedures were approved by the National Animal Experiment Board of Finland and carried out in accordance with the guidelines of The Finnish Act on Animal Experimentation. Soat2 -/- mice Human APOB 100 transgenic, Ldlr -/- ,Soat2 -/- , and human APOB 100 transgenic, Ldlr -/- expressing sterol O-acyltransferase 2 (SOAT2) mice were fed on a diet rich in cis-monounsaturated fat 26 for 8 months, after which plasma was collected and LDL particles were isolated by ultracentrifugation. These animal procedures were approved by the Institutional Animal Care and Use Committee at Wake Forest University Health Sciences. Assessment of atherosclerotic lesions The degree of atherosclerosis was assessed by Sudan IV staining of the aortas as described in Supplementary material online. Lipid mass spectrometry analyses LDL lipids were analysed by mass spectrometry as described in Supplementary material online. Circular dichroism analyses The secondary structure of apoB-100 in LDL particles was determined by circular dichroism as described previously 27 and in Supplementary material online. Cell culture Cell culture material and methods are available in Supplementary material online. Mathematical modelling and statistical analyses Mathematical modelling and statistical analyses are available in Supplementary material online. Results Measurement of the susceptibility of LDL to aggregate ex vivo We developed a novel, reproducible method to quantify donor-todonor variation in the susceptibility of LDL particles to aggregate (see Supplementary material online,Methods and Figures S1–S3). LDL was isolated from plasma samples by ultracentrifugation, aggregation of each LDL preparation was induced ex vivo by incubation with hrSMase, and the kinetics of aggregation were followed in real time by measuring the growth of the aggregates by dynamic light scattering (Figure 1A). Other agents to modify LDL ex vivo produced far smaller aggregates with negligible discrimination between individuals (see Supplementary material online,Figure S1a–e). In the absence of any modifying agent, LDL particles show no sign of aggregation (Supplementary material online,Methods). We used our hrSMase-based assay to screen LDL aggregation susceptibility in samples derived from the Finnish Health 2000 Health Examination Survey, 20 which comprised largely healthy individuals (n= 100, Table 1,Figure 1B). To quantify the inter-individual variation in the aggregation susceptibility of LDL, we first developed a population-based generalized mixed-effect model (see Supplementary material online,Figure S3a). As described in the Supplementary material online,Methods, these data revealed that the inflection points in the curves of aggregate size vs. incubation time readily distinguished the aggregation susceptibility of the different LDL samples. Further, we found that LDL aggregate size at the 2-h time point correlated tightly and significantly with the inflection point (see Supplementary material 2564 M. Ruuth et al. Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/27/2562/5049093 by Tampere University Library user on 22 August 2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . online, Figure S3b, rho = -0.961, P< 0.001). Importantly, the extent of aggregation at 2 h clearly identified subjects having extremely aggregation-prone LDL particles (Figure 1C, Quartile 1). Therefore, in further assays, aggregate size at this time point was used as a measure of LDL aggregation susceptibility. The susceptibility of LDL to aggregate predicts future cardiovascular deaths We next measured the aggregation susceptibility of LDL isolated from plasma samples derived from patients with clinically diagnosed coronary artery disease (CAD). The samples were from a nested case–control study 28 that had been designed using samples from the Finnish Corogene study. 21 The cases in that study included all patients who had experienced coronary death within an average follow-up of 2.5 years. Control patients were selected from the group who had no cardiovascular events during the follow-up period (Stable CAD group), and they were pairwise matched based on conventional CAD risk factors, statin use, and coronary stenosis index. The plasma samples selected for this study (n= 48) were from non-diabetic males, all of whom had >_50% coronary stenosis (Table 2). We again observed substantial inter-individual differences in the aggregation susceptibility of the isolated LDL particles. Importantly, in the CAD Death group, LDL particles aggregated significantly faster than in the Stable CAD group, the median sizes of the aggregates after incubation for 2 h being 1500 nm (range 150–3200 nm) and 940 nm (range 90–1990 nm), respectively (Figure 1D). Moreover, the 2-h aggregate sizes of LDL samples in both CAD groups were significantly higher than in the 100 LDL samples obtained from the Health 2000 study; median 200 nm (range 60–2000 nm) (Figure 1D). LDL aggregation at 2 h was not associated with the initial sizes of LDL particles, nor did it associate significantly with plasma concentrations of LDL-C, apoB-100, Creactive protein (hsCRP), or lipoprotein (a), nor with statin use, age or smoking, but showed a negative correlation with plasma triglyceride levels (see Supplementary material online,Tables S1 and S2). LDL isolation by sequential ultracentrifugation LDL aggregation Plasma LDL LDL aggregation analysis Aggregate size (nm) Time (h) Time (h) Time (h) Time (h) Quartile Time Aggregate size Time Aggregate size D C B A CAD Death n=24 Stable CAD n=24 Health 2000 n=100 500 1000 1500 2000 2500 0 1234 1000 0 4000 6000 2000 024 6 1st quartile 2nd quartile 3rd quartile 4th quartile * *** *** Aggregate size at 2h (nm) hrSMase Aggregation data modeling 024 6 0246 024 6 Aggregate size at 2h (nm) 4000 3000 2000 Figure 1 Measurement of the susceptibility of low-density lipoprotein (LDL) from healthy human subjects and from coronary artery disease patients to aggregate ex vivo.(A) LDL is isolated from blood plasma by ultracentrifugation and aggregation was induced by incubation with human recombinant secretory sphingomyelinase (hrSMase) at pH 5.5. The size of LDL particles was measured before hrSMase treatment (time = 0 h), and formation of LDL aggregates was followed in real time by measuring their size with dynamic light scattering. (B) LDL particles were isolated from 100 plasma samples collected from the Finnish Health 2000 Health Examination Survey and the aggregation susceptibility of the particles was analysed. Based on LDL aggregate size at 2 h, the particles were divided into quartiles. (C) Size distributions of LDL aggregates at the 2 h time point. The box encompasses the middle 50% of the measured values; the horizontal line within each box shows the median of the measured values; the whiskers encompass the most extreme data point that is still no further from the margins of the box than 1.5 times the interquartile range. (D)Patients(n=48) from the Corogene study, having >50% stenosis in their coronary arteries were divided into two groups: (i) CAD death group, in which patients died of coronary events during an average 2.5-year follow-up period and (ii) stable CAD group, having no cardiovascular events during the follow-up period. The patients were matched for the conventional cardiovascular risk factors. LDL was isolated and LDL aggregation was induced by treatment with hrSMase. The box plot diagram shows the distribution of aggregate sizes after incubation for 2 h in the two groups from Corogene study and in 100 subjects from the Health 2000 study (all quartiles from Ccombined). Statistical differences between the groups were determined using Kruskal– Wallis test followed by Dunn’s test. P< 0.001 by Kruskal–Wallis test; *P< 0.05, ***P<0.001 by Dunn’s test. Aggregation-prone LDL predicts CAD death 2565 Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/27/2562/5049093 by Tampere University Library user on 22 August 2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . The susceptibility of LDL particles to aggregate strongly associates with the particle lipid composition The surface monolayer of LDL particles comprises phospholipids, free cholesterol, ceramides (Cer), and a single copy of apoB-100 as the principal structural apolipoprotein of the particle (Figure 2A). Phosphatidylcholines (PC) are the major phospholipid class, followed by sphingomyelins (SM), and lysophosphatidylcholines (LPC). The surface also contains small amounts of other classes of phospholipids and ceramides. The particle core contains mainly cholesteryl esters (CE) and triacylglycerols (TAG). The compositions of isolated LDL preparations from the Health 2000 and Corogene studies described above were determined by quantitative mass spectrometry-based lipidomics. Volcano plots show the significant (P< 0.05) correlations between LDL aggregation and the molar percentagesofspecificlipidsofthe LDL surface (Figure 2B, C) and core (Figure 3A, B). Several sphingolipids (SMs and various forms of Cer) correlated positively (red) and various phosphatidylcholine (PC) species correlated negatively (blue) with LDL aggregation. Regarding the core lipids of LDL, the degree of LDL aggregation correlated negatively particularly with several 48–52 carbonTAGsinbothcohorts(Figure 3A, B). Of note, of the lipids that significantly associate with LDL aggregation, the ceramides and TAG 50:4 differed significantly between the Stable CAD and CAD Death groups, ceramides being higher and TAG 50:4 lower in the case group. Direct enrichment LDL with different phospholipids changes aggregation susceptibility of LDL and conformation of apoB-100 To determine causal effects of lipid composition on LDL aggregation, we next isolated LDL from four healthy volunteers and enriched the LDL with SM 18:1/16:0, PC 16:0/18:1, or LPC 16:0. Changes in the relative proportions of phospholipids in these lipid-enriched LDL particles were small (see Supplementary material online,Figure S4a) and the final compositions were well within ranges we observed in other human LDL samples. Although the aggregability of control LDL from the four donors varied considerably (see Supplementary material online,Figure S4b, black lines), in each case the LDL preparations enriched with SM became more susceptible to aggregation during incubation with hrSMase, while LDL preparations enriched with PC or LPC became less susceptible. We know from previous studies that SMase-treatment of LDL induces conformational changes in apoB100 that expose otherwise hidden segments of apoB-100 that mediate particle aggregation. 27 Here,weshowthatenrichmentofLDL with SM enhanced SMase-induced conformational changes in apoB100 (see Supplementary material online,Figure S4c, d). In human subjects, decreases in LDL-SM by dietary change, or by PCSK9 inhibition decreased LDL aggregation susceptibility To determine if a change in LDL lipid composition changes the aggregation susceptibility of LDL, we analysed samples from two different interventions: (i) SYSDIET, a dietary intervention, in which healthy volunteers with features of the metabolic syndrome were randomly assigned to either a Healthy Nordic diet (n=33)ortoaControldiet (n= 24) for 18 or 24 weeks 22,23 and (ii) EQUATOR, a randomised placebo-controlled phase II trial of a fully human monoclonal antibody RG7652 that inhibits the function of proprotein convertase subtilisin/kexin type 9 (PCSK9, n= 25; placebo, n= 15). Fasting plasma samples were obtained at baseline and 29 days after treatment. 24 First, we analysed the aggregation of LDL from plasma samples that had been collected from the Finnish participants in the SYSDIET study. Supplementary material online,Table S3 shows the clinical characteristics of these subjects at baseline and the end of the study, and Supplementary material online,Figure S5a shows the changes in ................................................................................................. Table 1 Clinical characteristics of Health 2000 Health Examination survey participants assessed in this study Characteristics Health 2000 Number of subjects a 100 Gender (male) a 50 (50%) Age (years) b 40 (33–48) Current smoker a 15 (15%) Blood pressure: syst/diast (mmHg) b 121/78 (110–132/68–85) Body mass index (kg/m 2 ) b 24.2 (22.5–28.1) Glucose (mmol/L) b 5.2 (5.0–5.5) Diabetes a 1 (1%) Statin (n= 91) a 4 (4%) Total cholesterol (mmol/L) b 5.5 (4.8–6.5) LDL-C (mmol/L) b 3.1 (2.6–4.0) HDL-C (mmol/L) b 1.3 (1.1–1.6) TG (mmol/L) b 1.3 (0.9–1.9) C-reactive protein (mg/L) b 0.6 (0.2–1.8) a Number of cases (%). b Median (interquartile range). ................................................................................................. Table 2 Baseline characteristics of Corogene study patients assessed in this study Characteristics CAD death Stable CAD Number of patients 24 24 Gender (male) a 24 (100) 24 (100) Age (years) b 66 (60–73) 66 (60–73) Current smoker a 8 (33) 8 (33) Hypertension a 18 (75) 13 (54) Body mass index (kg/m 2 ) b 26.1 (25.1–29.8) 25.6 (24.8–27.4) Diabetes a 0 (0) 0 (0) Statin a 13 (54) 13 (54) Coronary stenosis index b 14 (3–28) 15 (2–42) Total cholesterol (mmol/L) b 3.5 (2.9–4.1) 3.8 (3.1–4.4) LDL-C (mmol/L) b 2.1 (1.6–2.5) 2.1 (1.6–2.7) HDL-C (mmol/L) b 0.8 (0.7–1.0) 0.9 (0.9–1.1) TG (mmol/L) b 2.5 (2.1–2.8) 2.9 (1.9–3.7) C-reactive protein (mg/L) b 4.5 (2.3–12) 0.8 (0.7–2.0) a Number of cases (%). b Median (interquartile range). 2566 M. Ruuth et al. Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/27/2562/5049093 by Tampere University Library user on 22 August 2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . the macroand micro-nutrient compositions of what each subject consumed based on food diaries at the beginning and at the end of the study. 22,23 In the Healthy Nordic diet group, LDL aggregation decreased in two-thirds of the participants, whereas in the control group, only small changes in LDL aggregation were observed (Figure 4A, B). To estimate how much of the changes in LDL aggregation could be attributed to the dietary changes, we constructed a multivariate model using data from the subjects in the Healthy Nordic diet group. The best model included just two components from the food diaries: changes in dietary vitamin E and changes in dietary sucrose (Table 3). Decreased aggregation susceptibility was associated with increased dietary vitamin E and decreased dietary sucrose consumption. An increase in dietary vitamin E is considered a useful marker of increased consumption of vegetable oils rich in polyunsaturated fatty acids, and both were significantly associated with increased proportion of PCs and decreased proportion of SMs in plasma LDL particles (see Supplementary Figure S5b). These lipidomics changes were also associated with reduced LDL aggregation susceptibility in the Healthy Nordic diet group (Figure 4Cand Supplementary material online, Figure S5b), but no significant associations were observed in the control group (see Supplementary material online,Figure S6a). Inhibition of PCSK9 is known to strikingly lower LDL-C, and we recently showed that PCSK9 inhibition also influences plasma and lipoprotein phospholipid composition. 29 The clinical characteristics of EQUATOR trial subjects at baseline and the end of the study are descripted in Supplementary material online, Table 4. In the treatment group of the EQUATOR trial, LDL aggregation susceptibility decreased in two-thirds of the subjects, whereas in the placebo group, only small changes in LDL aggregation occurred during the trial (Figure 4D, E). In addition, the overall change in aggregation susceptibility between the groups was significantly different between the two treatment groups (P= 0.035). The decrease in LDL aggregation in the treatment group correlated with an increase in several PC species and a decrease in several SM species (Figure 4F). In the control group, only PC 16:0/18:2 correlated significantly with decreased LDL aggregation susceptibility (see Supplementary material online,Figure S6b). Pharmacological and genetic interventions in vivo to render LDL resistant to aggregation To further examine our model linking changes in LDL lipids with changes in the susceptibility of LDL to aggregate, we carried out three interventions that had previously been shown to induce changes in LDL lipid composition and to decrease atherosclerosis in hypercholesterolaemic animals, but, remarkably, without changing the plasma p-value CE TAG SM Cer PC LPC ApoB-100 UC Intensity m/z Lipid MS A BC -0.4 -0.2 0.0 0.2 0.4 0.01 0.02 0.03 0.05 0.1 0.2 0.3 0.5 1 Cer 18:0/18:0 Cer 18:1/24:1 PC 16:0/20: 3 PC 18:0/20:3 Total PC Corogene: LDL surface lipids -0.295 0.317 Coefficient LPC 22:4 -0.4 -0.2 0.0 0.2 0.4 5e-07 5e-06 5e-05 0.0005 0.005 0.05 0.5 1 Cer 18:0/24:1 LPC 18:3 PC 16:0/16:1 PC 16:0/18:1 PC 16:0/20:3 PC 16:0/20:4 PC 16:0/22:5 PC 18:0/18:1 PC 18:0/20:3 PC 18:1/18:1 PC 18:1/20:4 Total PC SM 18:1/15:0 SM 18:1/16:0 SM 18:1/17:0 SM 18:1/18:0 SM 18:1/24:2 C 1 8 0 / 2 4 1 C 8 3 -0.469 0.417 Coefficient SM 18:1/16:1 SM 18:0/16:0 SM 18:1/14:0 SM 18:1/18:1 SM 18:1/14:1 Cer 18:1/26:1 SM 18:1/24:1 p-value Health 2000: LDL surface lipids LDL aggregation vs. LDL surface lipids (Spearman correlation coefficient) LDL aggregation vs. LDL surface lipids (Spearman correlation coefficient) LDL Figure 2 The susceptibility of low-density lipoprotein (LDL) to aggregate strongly correlates with the surface lipid composition of the particles. (A) LDL was isolated from plasma and LDL lipidome was analysed using mass spectrometry. Volcano plots showing Spearman correlation coefficients of LDL aggregate size at 2 h vs. LDL surface lipids in (B) Health 2000 samples and (C) in Corogene samples. Red circles indicate positive correlations, and blue circles indicate negative correlations. The identities of only those lipids with significance correlation values (P<0.05)areindicated.Cer, ceramide; LPC, lysophosphatidylcholine; PC, phosphatidylcholine; SM, sphingomyelin. Aggregation-prone LDL predicts CAD death 2567 Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/27/2562/5049093 by Tampere University Library user on 22 August 2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . concentrations of LDL-C. 30–32 In the first intervention, we administered a single intravenous bolus injection of large 100-nm ‘empty’ vesicles (LEVs, also known as large unilamellar vesicles) composed of a single lipid, PC 16:0/18:1, into human APOB100 transgenic/Ldlr -/- mice (n= 16) fed on a regular chow diet. Control APOB100 transgenic/Ldlr -/- littermates (n= 16) received an intravenous injection of an equivalent volume of PBS. Plasma was collected 1 h after the injection, and LDL was purified sequentially by ultracentrifugation and size-exclusion chromatography. Treatment with LEVs substantially altered LDL lipid composition in vivo (see Supplementary material online,Figure S7)and rendered LDL nearly completely resistant to aggregation ex vivo,even after 24 h of incubation with hrSMase (Figure 5Aand inset). In the second intervention, we suppressed SM biosynthesis in Ldlr -/- /Apob 100/100 -mice using myriocin, an inhibitor of serinepalmitoyl transferase, the rate-limiting enzyme in SM biosynthesis. Inhibition of this enzyme in mice leads to the generation of SMdepleted lipoprotein particles. 31 After 10 weeks of a high-fat atherogenic diet combined with three intraperitoneal injections/week of myriocin or PBS (n= 11 per group), the animals were sacrificed. Treatment with myriocin did not change plasma cholesterol or triglyceride levels, but LDL particles from the myriocin-injected mice contained a far lower proportion of SM (see Supplementary material online,Figure S8) and were less susceptible to hrSMase-induced aggregation than LDL from PBS-injected control littermates (Figure 5B). In addition, atherosclerotic lesion areas were smaller in myriocintreated mice than in control mice, particularly in the region of the abdominal aorta (Figure 5C). In the third intervention, we investigated the effect of the composition of the lipid core of LDL particles on their susceptibility to aggregate by using mice deficient in SOAT2, and enzyme also known as acyl-CoA: cholesterol acyltransferase-2 or ACAT2. LDL was isolated from the plasma of APOB100 transgenic/Ldlr -/- /Soat2 -/- mice (n=5) and APOB100 transgenic/Ldlr -/- /Soat2 þ/þ littermates (n= 3). LDL particles from SOAT2-deficient mice are characterized by enrichment in polyunsaturated CEs and TAGs, when compared with LDL from control mice. 26 Here, we found that LDL particles from Soat2 -/- mice were particularly aggregation-resistant (Figure 5D), consistent with our data from human LDL (Figure 3). Aggregated LDL induces MMP-7 secretion from macrophage foam cells and activates T-cells in vitro To study maladaptive cellular responses relevant to atherosclerosis, we examined the effects of hrSMase-aggregated LDL vs. native LDL on cultured human primary monocyte-derived macrophages and murine T-cell hybridomas that had been raised against oxidized LDL. 33 Aggregated LDL induced accumulation of cholesteryl esterrich lipid droplets in the human primary monocyte-derived macrophages (Figure 6A, B), consistent with prior literature. 16 We also analysed the concentrations of several matrix metalloproteinases (MMPs) in the culture media and found that foam cells induced with hrSMase-treated LDL, but not with acetylated LDL, secrete increased amounts of MMP-7 (Figure 6C), a protease considered to be an AB -0.4 -0.2 0.0 0.2 0.4 0.01 0.02 0.03 0.05 0.1 0.2 0.3 0.5 1 CE 18:2 Total CE TAG 48:2 TAG 50:2 TAG 50:3 Total TAG -0.364 0.325 Coefficient TAG 50:4 TAG 52:1 -0.4 -0.2 0.0 0.2 0.4 5*10 -7 5*10 -6 5*10 -5 0.0005 0.005 0.05 0.5 1 CE 14:1 CE 16:0 CE 18:2 CE 20:3 CE 22:4 TAG 48:0 -0.380 0.236 Coefficient CE 14:0 TAG 48:1 TAG 52:1 TAG 50:1 CE 16:1 CE 17:1 CE 20:1 Corogene: LDL core lipids Health 2000: LDL core lipids LDL aggregation vs. LDL core lipids (Spearman correlation coefficient) LDL aggregation vs. LDL core lipids (Spearman correlation coefficient) p-value p-value Increased aggregationDecreased aggregation Increased aggregationDecreased aggregation Figure 3 The susceptibility of low-density lipoprotein (LDL) to aggregate strongly correlates with the core lipid composition of the particles. Volcano plots showing Spearman correlation coefficients of LDL aggregate size at 2 h vs. LDL core lipids (A) in Health 2000 samples and (B)in Corogene samples. Red circles indicate positive correlations, and blue circles indicate negative correlations. The identities of only those lipids with significance correlation values (P< 0.05) are indicated. CE, cholesteryl ester; TAG, triacylglycerol. 2568 M. Ruuth et al. Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/27/2562/5049093 by Tampere University Library user on 22 August 2018 LDL aggregation vs. LDL surface lipids (Spearman correlation coefficient) p-value CB 0 weeks 18/24 weeks 0 weeks 18/24 weeks LDL LIPID CHANGES: Healthy Nordic diet -0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.0005 0.001 0.002 0.005 0.01 0.02 0.05 0.1 0.2 0.5 1 Total PC PC 16:0/18:1 PC 18:0/22:5 PC 18:0/18:1 PC 18:0/20:3 Total SM SM 18:1/15:0 SM 18:1/16:0 SM 18:1/21:0 SM 18:1/23:0 SM 18:1/23:1 -0.511 0.587 Coefficient PC 16:0/18:1 SM 18:1/18:0 n=33 5000 4000 3000 2000 1000 0 5000 4000 3000 2000 1000 0 A FED LDL AGGREGATION: Healthy Nordic diet n=33 LDL AGGREGATION: Control diet n=24 Aggregate size at 2h (nm) Aggregate size at 2h (nm) 0.0 0.2-0.2-0.4-0.6 0.60.4 0.005 0.01 0.02 0.05 0.1 0.2 0.5 1 -0.548 0.556 PC 18:0/18:2 PC 18:0/22:5 PE 18:0/18:2 PC 16:0/20:2 PC 18:0/20:3 Total PC SM 18:1/18:1 PC 16:0/20:5 PC 18:0/20:5 SM 18:1/16:1 SM 18:1/22:0 p-value LDL aggregation vs. LDL surface lipids (Spearman correlation coefficient) LDL LIPID CHANGES: PCSK9 inhibitor 800 600 400 200 0 Day 0 Day 29 1000 800 600 400 200 0 Day 0 Day 29 Aggregate size at 2h (nm) Aggregate size at 2h (nm) LDL AGGREGATION: Placebo n=15 LDL AGGREGATION: PCSK9 inhibitor n=25 n=25 Coefficient Figure 4 A dietary intervention and PCSK9 inhibition in human subjects improves their low-density lipoprotein (LDL) composition and renders their particles less susceptible to aggregate. Plasma samples were obtained from the SYSDIET-study, where participants were placed on either an isocaloric healthy Nordic diet (n= 33) or a control diet (n= 25) for 18 or 24 weeks and from the EQUATOR study, a randomized placebo-controlled phase II trial of a monoclonal antibody inhibiting the function of PCSK9, RG7652, (n= 25), or placebo (n= 15) for 29 days. LDL was isolated, and aggregation analysed from samples before and after the diet/treatment period. (Aand B) LDL aggregate sizes at the 2-h time point are shown in the diet group and control group before and after the diet period. Each line represents one subject and blue lines show a decrease and red lines an increase in aggregate size. (Dand E) LDL aggregate sizes at the 2-h time point are shown in the PSCK9 inhibitor group and placebo group before and after the treatment period. Each line represents one subject and blue lines show a decrease and red lines an increase in aggregate size. (Cand F)Volcanoplot showing the Spearman correlation coefficients of LDL aggregate size at 2 h vs. LDL surface lipids in the SYSDIET study and in the EQUATOR study. PC, phosphatidylcholine; PE, phosphatidylethanolamine; SM, sphingomyelin. .................................................. .................................................. .................................................. .................................................. ............ Table 3 Multiple regression explaining the effect of dietary changes on changes in the 2 h aggregate size in the SYSDIET group Predictors bSE bbtP-value R 2 Adjusted R 2 F Intercept 2450.2 579.9 4.23 <0.001 0.494 0.456 13.16 DDietary Vitamin E -1830.7 362.3 -0.746 -5.05 <0.001 DDietary sucrose 562.3 208.3 0.398 2.70 0.012 n= 31. Aggregation-prone LDL predicts CAD death 2569 Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/27/2562/5049093 by Tampere University Library user on 22 August 2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . important contributor to weakening, and ensuing rupture of atherosclerotic plaques. 34 In parallel with macrophages, T cells are also recruited to atherosclerotic lesions. Triggered by LDL that is taken up and presented by antigen-presenting cells, T cells can accelerate atherosclerosis in hypercholesterolaemic animals and promote features associated with plaque instability. 18 Paradoxically, T-cell hybridomas raised against oxidized LDL do not react to oxidized LDL. 33 Nonetheless, T cells with a similar set of clonotypic T-cell receptors in hypercholesterolaemic mice have been shown to participate in the growth of their atherosclerotic plaques. 18 Here, we found that the degree of LDL aggregation induced by SMase associated positively with the degree of T-cell activation, as measured by the secretion of interleukin2(Figure 6D, left panel). In contrast, consistent with earlier data, 33 oxidized LDL inhibited the T-cell response (Figure 6D, right panel). Discussion In this study, we show that the susceptibility of LDL particles to aggregate in the presence of hrSMase varies significantly amongst human subjects and depends on the lipid composition of their LDL particles. The presence of aggregation-prone LDL was associated with future CAD deaths independently of conventional CAD risk factors including plasma LDL-C concentration, smoking, and hypertension. Importantly, we show that the susceptibility of LDL particles to aggregate can be favourably modified in humans by nutritional and 0 500 1000 1500 2000 2500 3000 3500 4000 4500 5000 0123 4 65 Aggregate size (nm) Time (h) Control Myriocin 0 20 40 60 80 100 120 140 160 180 0123456 Time (h) Control Myriocin * * * Plaque (% of aorta) AB CD 0 1 2 3 024 ** 0 20 40 60 80 100 120 140 160 180 200 02 135 4 *** *** *** *** ** Aggregate size (nm) Time (h) SOAT +/+ 2 2 -/- SOAT Control LEV Time (h) Aggregate size * * * Aggregate size (nm) 0 10 20 30 40 50 60 Arch Thoracic Abdominal Control Myriocin * Figure 5 Pharmacological and genetic interventions that favourably alter low-density lipoprotein (LDL) lipid composition in vivo in hypercholesterolaemic mice render their LDL aggregation-resistant. (A)HumanAPOB transgenic/LDLr / mice were given a single intravenous injection of large ‘empty’ vesicles (LEVs) made from PC 16:0/18:1 or equivalent volume of PBS (control, n= 8 per group). After 1 h, plasma was collected, LDL isolated, and aggregation induced by treatment with hrSMase. LDL aggregation was followed by dynamic light scattering at the indicated time points. The insert shows LDL aggregation for up to 24 h. (B)LDLr / /Apob 100/100 mice were simultaneously started on an atherogenic western-type diet and intraperitoneal injections three times per week of either myriocin, and inhibitor of SM biosynthesis, or PBS (n= 11 mice per group). Diet and injections continued for 10 weeks. LDL was isolated, then treated with hrSMase, and particle aggregation was followed by dynamic light scattering at the indicated time points. (C) Representative aortas from a control mouse and a myriocin-treated mouse stained with Sudan IV. The extent of atherosclerosis was determined by measuring the amounts of Sudan IV positive areas in the aortas. (D) LDL was isolated from the plasma of human APOB transgenic/ LDLr / /Soat2 / mice and human APOB transgenic/LDLr / /Soat2 þ/þ littermates. LDL was treated with hrSMase and LDL aggregation followed by dynamic light scattering at the indicated time points. The line and column graphs display averages ± standard deviations. *P<0.05, **P<0.01,and ***P<0.001byStudent’st-test. 2570 M. Ruuth et al. Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/27/2562/5049093 by Tampere University Library user on 22 August 2018